Portal de Periódicos da CAPES

Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty

2013; American College of Physicians; Volume: 159; Issue: 7 Linguagem: Inglês

10.7326/0003-4819-159-7-201310010-00018

1539-3704

David R. Anderson, Michael Dunbar, Susan R. Kahn,

Atrial Fibrillation Management and Outcomes

LettersOctober 1, 2013Aspirin Versus Low-Molecular-Weight Heparin After Total Hip ArthroplastyDavid R. Anderson, MD, Michael J. Dunbar, MD, and Susan R. Kahn, MDDavid R. Anderson, MDFrom Dalhousie University, Halifax, Nova Scotia, Canada; and McGill University, Montréal, Québec, Canada., Michael J. Dunbar, MDFrom Dalhousie University, Halifax, Nova Scotia, Canada; and McGill University, Montréal, Québec, Canada., and Susan R. Kahn, MDFrom Dalhousie University, Halifax, Nova Scotia, Canada; and McGill University, Montréal, Québec, Canada.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-159-7-201310010-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Drs. Granziera and Cohen for their comments about our recent EPCAT (Extended Prophylaxis Comparing Low Molecular Weight Heparin to Aspirin in Total Hip Arthroplasty) study, which provides further evidence about the benefit of aspirin for the prevention of VTE after total hip arthroplasty (1). As Drs. Granziera and Cohen point out, patients randomly assigned to receive either low-molecular-weight heparin or aspirin had low rates of major risk factors for VTE and bleeding. More than 90% of the participants had none of the major risk factors cited for thromboembolism, and more than 98% had no history of ...References1. Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158:800-6 LinkGoogle Scholar2. Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, and Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:3675. [PMID: 22700784] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Dalhousie University, Halifax, Nova Scotia, Canada; and McGill University, Montréal, Québec, Canada.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2191. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty David R. Anderson , Michael J. Dunbar , Eric R. Bohm , Etienne Belzile , Susan R. Kahn , David Zukor , William Fisher , Wade Gofton , Peter Gross , Stephane Pelet , Mark Crowther , Steven MacDonald , Paul Kim , Susan Pleasance , Nicki Davis , Pantelis Andreou , Philip Wells , Michael Kovacs , Marc A. Rodger , Tim Ramsay , Marc Carrier , and Pascal-Andre Vendittoli Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty Serena Granziera and Alexander T. Cohen Metrics October 1, 2013Volume 159, Issue 7Page: 502-503KeywordsAnticoagulantsArthroplastyDatabasesDeep vein thrombosisHemorrhageHeparinKneesLung and intrathoracic tumorsMedical risk factorsOutpatientsProphylaxisPulmonary embolismSurgerySystematic reviewsThromboembolismTotal hip arthroplastyTotal hip replacementTotal knee arthroplasty ePublished: 1 October 2013 Issue Published: October 1, 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...